sk&f-38393 has been researched along with Dyskinesia, Drug-Induced in 48 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Haloperidol-induced VC were inhibited by the s." | 1.28 | Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine. ( Collu, M; Diana, M; Gessa, GL; Mura, A, 1992) |
| "The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats." | 1.28 | Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. ( Lucki, I; McGonigle, P; Neisewander, JL, 1991) |
| "Treatment with haloperidol (0." | 1.28 | Drug-induced purposeless chewing: animal model of dyskinesia or nausea? ( Iversen, SD; Rupniak, NM; Tye, SJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (20.83) | 18.7374 |
| 1990's | 16 (33.33) | 18.2507 |
| 2000's | 12 (25.00) | 29.6817 |
| 2010's | 8 (16.67) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Kiessling, CY | 1 |
| Lanza, K | 1 |
| Feinberg, E | 1 |
| Bishop, C | 1 |
| Andreoli, L | 1 |
| Abbaszadeh, M | 1 |
| Cao, X | 1 |
| Cenci, MA | 2 |
| Arcuri, L | 1 |
| Novello, S | 1 |
| Frassineti, M | 1 |
| Mercatelli, D | 1 |
| Pisanò, CA | 1 |
| Morella, I | 1 |
| Fasano, S | 1 |
| Journigan, BV | 1 |
| Meyer, ME | 1 |
| Polgar, WE | 1 |
| Brambilla, R | 1 |
| Zaveri, NT | 1 |
| Morari, M | 1 |
| Suárez, LM | 1 |
| Solís, O | 1 |
| Caramés, JM | 1 |
| Taravini, IR | 1 |
| Solís, JM | 1 |
| Murer, MG | 1 |
| Moratalla, R | 1 |
| Iderberg, H | 1 |
| Rylander, D | 1 |
| Bimpisidis, Z | 1 |
| Farré, D | 1 |
| Muñoz, A | 2 |
| Moreno, E | 2 |
| Reyes-Resina, I | 1 |
| Canet-Pons, J | 1 |
| Dopeso-Reyes, IG | 1 |
| Rico, AJ | 1 |
| Lluís, C | 1 |
| Mallol, J | 1 |
| Navarro, G | 2 |
| Canela, EI | 1 |
| Cortés, A | 2 |
| Labandeira-García, JL | 2 |
| Casadó, V | 2 |
| Lanciego, JL | 2 |
| Franco, R | 2 |
| Casadó-Anguera, V | 1 |
| Petrovic, M | 1 |
| Xie, CL | 1 |
| Lin, JY | 1 |
| Wang, MH | 1 |
| Zhang, Y | 1 |
| Zhang, SF | 1 |
| Wang, XJ | 1 |
| Liu, ZG | 1 |
| Carta, AR | 2 |
| Frau, L | 2 |
| Pinna, A | 2 |
| Morelli, M | 2 |
| Fisone, G | 2 |
| Aubert, I | 1 |
| Guigoni, C | 1 |
| Håkansson, K | 1 |
| Li, Q | 1 |
| Dovero, S | 1 |
| Barthe, N | 1 |
| Bioulac, BH | 1 |
| Gross, CE | 2 |
| Bloch, B | 1 |
| Bezard, E | 2 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Rosengarten, H | 4 |
| Bartoszyk, GD | 1 |
| Quartermain, D | 1 |
| Lin, Y | 1 |
| Tomiyama, K | 1 |
| Makihara, Y | 1 |
| Yamamoto, H | 1 |
| O'Sullivan, G | 1 |
| Nally, RE | 1 |
| Tighe, O | 1 |
| Kinsella, A | 1 |
| Fienberg, AA | 1 |
| Grandy, DK | 1 |
| Sibley, DR | 1 |
| Croke, DT | 1 |
| Koshikawa, N | 2 |
| Waddington, JL | 1 |
| Zhang, H | 1 |
| Ma, L | 1 |
| Wang, F | 1 |
| Chen, J | 1 |
| Zhen, X | 1 |
| Lucia, F | 1 |
| Annalisa, P | 1 |
| Pontis, S | 1 |
| Silvia, P | 1 |
| Simola, N | 1 |
| Nicola, S | 1 |
| Schintu, N | 1 |
| Nicoletta, S | 1 |
| Micaela, M | 1 |
| Schweitzer, JW | 3 |
| Friedhoff, AJ | 3 |
| LaHoste, GJ | 1 |
| Marshall, JF | 1 |
| Glenthøj, B | 2 |
| Kaur, S | 1 |
| Starr, MS | 1 |
| Starr, BS | 1 |
| Storey, E | 1 |
| Cipolloni, PB | 1 |
| Ferrante, RJ | 1 |
| Kowall, NW | 1 |
| Beal, MF | 1 |
| Bolwig, TG | 1 |
| Hemmingsen, R | 1 |
| Ohno, Y | 1 |
| Ishida-Tokuda, K | 1 |
| Ishibashi, T | 1 |
| Nakamura, M | 1 |
| Neal-Beliveau, BS | 1 |
| Joyce, JN | 1 |
| Ikeda, H | 1 |
| Adachi, K | 1 |
| Hasegawa, M | 1 |
| Sato, M | 1 |
| Hirose, N | 1 |
| Cools, AR | 2 |
| Canales, JJ | 1 |
| Iversen, SD | 3 |
| Van Kampen, JM | 1 |
| Stoessl, AJ | 1 |
| Boraud, T | 1 |
| Bioulac, B | 1 |
| Naidu, PS | 1 |
| Kulkarni, SK | 1 |
| Peacock, L | 2 |
| Gerlach, J | 4 |
| Van De Witte, SV | 1 |
| Groenewegen, HJ | 1 |
| Voorn, P | 1 |
| Diana, M | 1 |
| Collu, M | 1 |
| Mura, A | 1 |
| Gessa, GL | 1 |
| Lublin, H | 2 |
| Caporali, MG | 1 |
| Scotti de Carolis, A | 1 |
| Popoli, P | 1 |
| Spooren, WP | 1 |
| Piosik, PA | 1 |
| Neisewander, JL | 1 |
| Lucki, I | 1 |
| McGonigle, P | 1 |
| Rupniak, NM | 2 |
| Tye, SJ | 1 |
| Boyce, S | 1 |
| Steventon, MJ | 1 |
| Braun, A | 2 |
| Mouradian, MM | 2 |
| Mohr, E | 1 |
| Fabbrini, G | 2 |
| Chase, TN | 2 |
| Bédard, PJ | 2 |
| Boucher, R | 2 |
| Tamminga, CA | 1 |
| Egawa, M | 1 |
| Falardeau, P | 1 |
| Bouchard, S | 1 |
| Di Paolo, T | 1 |
| Johansson, P | 1 |
| Levin, E | 1 |
| Gunne, L | 1 |
| Ellison, G | 1 |
| Kistrup, K | 1 |
| Korsgaard, S | 1 |
| Gerhardt, S | 1 |
| Gerber, R | 1 |
| Liebman, JM | 1 |
1 trial available for sk&f-38393 and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Basal Ganglia Diseases; Ben | 1989 |
47 other studies available for sk&f-38393 and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2020 |
Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzimida | 2021 |
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetamides; Animals; Antiparkinson Agent | 2018 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral | 2014 |
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; | 2013 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatu | 2015 |
Hints on the Lateralization of Dopamine Binding to D1 Receptors in Rat Striatum.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Corpus Striatum; | 2016 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Ki | 2016 |
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2010 |
Monitoring dyskinesia with Zif.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Biomarker | 2010 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2005 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Behavior, | 2006 |
Disruption of orofacial movement topographies in congenic mutants with dopamine D5 but not D4 receptor or DARPP-32 transduction 'knockout'.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Chromans; Dopamine and cAMP-Reg | 2006 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease M | 2007 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St | 2008 |
Induction of oral dyskinesias in naive rats by D1 stimulation.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Benzazepines; Dysk | 1983 |
Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Dopamine Agoni | 1994 |
Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Apomorphi | 1993 |
Possible genetic factors underlying the pathophysiology of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Apomorphi | 1994 |
Role of D1 receptor mechanisms in the potentiation of motor responses to L-dopa and apomorphine by MK 801 in the reserpine-treated mouse.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dizocilpine Maleat | 1994 |
Movement disorder following excitotoxin lesions in primates.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Dyskinesia, Drug-I | 1994 |
Effects of chronic discontinuous and continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756).
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Benzofurans; Dopa | 1993 |
Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Avoidance | 1997 |
Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, | 1998 |
Effects of chronic haloperidol and clozapine on vacuous chewing and dopamine-mediated jaw movements in rats: evaluation of a revised animal model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1999 |
Dynamic dopamine receptor interactions in the core and shell of nucleus accumbens differentially coordinate the expression of unconditioned motor behaviors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Benzopyrans; | 2000 |
Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Behavior, | 2000 |
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2001 |
Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Anticonvulsants; Antipsychotic | 2000 |
Aberrant behavioral effects of a dopamine D1 receptor antagonist and agonist in monkeys: evidence of uncharted dopamine D1 receptor actions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Arousal; Behavior, Animal; Cebu | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocil | 2002 |
Haloperidol-induced vacuous chewing in rats: suppression by alpha-methyl-tyrosine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; Animals; Antipsych | 1992 |
Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1992 |
N-ethyl-carboxamide adenosine inhibits perioral dyskinesias induced by sulpiride + SKF 38393 in rabbits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Adenosine-5'-(N-ethylcarboxam | 1992 |
Dopamine D1 receptors in the sub-commissural part of the globus pallidus and their role in oro-facial dyskinesia in cats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Cats; Dyskinesia, | 1991 |
Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain; Caudat | 1991 |
Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Disease M | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Effect of D1 receptor stimulation in normal and MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1989 |
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Benzazepines; Dyskinesia, Drug-Induced; | 1988 |
Diminished D2 dopamine receptor function and the emergence of repetitive jaw movements.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Disease Models, A | 1988 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; | 1988 |
Opposite effects of a D1 and a D2 agonist on oral movements in rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Dyskinesia, Drug- | 1987 |
Effect of selective D1 and D2 dopamine receptor antagonists and agonists in Cebus monkeys: implications for acute and tardive dyskinesias. A preliminary report.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acute Disease; Animals; Benzazepines; Bi | 1987 |
SCH 23390 dissociated from conventional neuroleptics in apomorphine climbing and primate acute dyskinesia models.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Benzazepines; Benz | 1985 |